医学
内科学
肝细胞癌
免疫系统
肿瘤科
临床终点
胃肠病学
免疫检查点
人口
临床研究阶段
不利影响
临床试验
免疫疗法
免疫学
环境卫生
作者
Yan Sun,Qing Li,Jianming Xu,Jun Liang,Ying Cheng,Shu Li,Limin Zheng,Bin Ye,Kun Meng,Shukui Qin
标识
DOI:10.1200/jco.2018.36.15_suppl.4077
摘要
4077 Background: HCC was characterized with high heterogeneity and immune “tolerogenic”. Despite of immune checkpoint inhibitors have demonstrated promising results with improved overall survival, a significant fraction of advanced HCC patients are still left with limited treatment options and poor survival. The purpose of this study is to determine the safety, clinical activity and immune dynamic biomarkers of a small molecule icaritin, IL-6/STAT3 immune-modulator in advanced HCC. Methods: Major eligibility criteria include histologically confirmed unresectable HCC patients with Child-Pugh Class A or B liver function. Total of 70 advanced HCC patients were enrolled and administrated with 600 mg b.i.d. Primary endpoints were TTP, secondary endpoints were safety, OS, and DCR. Local disease control was defined as no progressive disease (PD) by RECIST. Kaplan-Meier analysis was utilized for OS assessment. Immune dynamic of NLR, IL-6 and baseline PD-L1 expression of immune cells was evaluated, retrospectively. Results: There was no ≥grade III drug related AE observed in all enrolled 70 advanced HCC patients. Objective response evaluation in per-protocol population showed PR (1.6%), SD (32.8%) and PD (59.0%) and median overall survival (OS) 254day (95% CI, 172-296). DCR was achieved 34.4% (95% CI, 22.7-47.7%); Median OS for the PD-L1-positive (n = 9) and negative (n = 24) subgroups were 389 (95% CI, 80-522) vs. 286.5days (95%CI, 135-482), for IL-6-advantage (n = 24) and disadvantage (n = 16) subgroups were 366.5 (95% CI, 277-566) vs. 157days (95% CI, 125-254), for NLR-advantage (n = 27) and disadvantage (n = 23) subgroups were 295(95% CI, 235-509) vs. 178days (95% CI, 135-296), respectively. Conclusions: Icaritin has demonstrated its favorable clinical safety and immune-modulation clinical efficacy. The improved OS was implicated in the subgroups of advanced HCC patients including PD-L1-positive immune cell expression. Both safety and immune-response efficacy are warranted for the phase III trial. Clinical trial information: NCT01972672.
科研通智能强力驱动
Strongly Powered by AbleSci AI